What We're Reading: Page 133
Industry reads hand-picked by our editors
Feb 10, 2022
-
The Financial Times
Biotechs face cash crunch after stock market ‘bloodbath’
-
Associated Press
Biden puts focus on drug prices as he tries to revive agenda
-
FirstWord Pharma
US lawmakers urge HHS to step in over price of Astellas' Xtandi
-
MIT Technology Review
Meet the scientist at the center of the covid lab leak controversy
Feb 09, 2022
-
Bloomberg
Glaxo Expects Profit to Rise as Drugmaker Prepares for Split
-
Associated Press
FDA's agenda in limbo as Biden's nominee stalls in Senate
-
Endpoints News
With first human data, long-struggling Silence Therapeutics leaps into next big cardiovascular race
-
FierceBiotech
Seismic emerges with $101M, Harvard billionaire founder and leadership team fresh off $1.9B exit
Feb 08, 2022
-
POLITICO
Biden’s top science adviser, Eric Lander, resigns amid reports of bullying
-
The New York Times
J.&J. Pauses Production of Its Covid Vaccine Despite Persistent Need
-
STAT
Biosplice's massive valuation turned heads. Now, layoffs raise questions
-
Reuters
Novavax underdelivers on COVID vaccine promises
Feb 07, 2022
-
The Washington Post
Biden administration moves to rev up support for nominee Califf to head FDA
-
Bloomberg
Moderna’s HIV Vaccine Trial Will Advance Many Companies’ mRNA Plans
-
POLITICO
Biden’s top science adviser bullied and demeaned subordinates, according to White House investigation
-
STAT
FDA regulator gives cool reception to drug Lilly licensed from Chinese firm
Feb 04, 2022
-
The Boston Globe
Eleven years after buying Genzyme, Sanofi officially ditches subsidiary's storied name
-
Bloomberg
Merck Covid Pill Molnupiravir Fumble Gives Pfizer $17 Billion Win
-
The New York Times
F.D.A. Nominee Faces Steep Climb to Senate Confirmation
-
Nature
South African scientists copy Moderna's COVID vaccine
Feb 03, 2022
-
Associated Press
Doctors: Cancer patients cured a decade after gene therapy
-
The New York Times
The Covid Vaccine We Need Now May Not Be a Shot
-
Endpoints News
Al Sandrock makes his first post-Biogen move, joining turnaround effort at a troubled gene therapy startup
-
Reuters
J&J to record $610 million charge related to skin disease drug
Previous
